Antioxidants as treatment for neurodegenerative disorders

Expert Opinion on Investigational Drugs

Volumn 11, Issue 10, 2002, Pages 1407-1435

  Moosmann, Bernd ^a   Behl, Christian ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Antioxidant; Clinical trial; Drug design; Free radical; Huntington's disease; Metabolic stabiliser; Neuroprotection; Oxidative stress; Parkinson's disease; Vitamin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 7 NITROINDAZOLE; ACETYLCARNITINE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOMORPHINE; CLIOQUINOL; CREATINE; DEFEROXAMINE; DICLOFENAC; EBSELEN; EPIGALLOCATECHIN GALLATE; ESTROGEN; FLAVONOID; GINKGO BILOBA EXTRACT; IDEBENONE; LEVODOPA; MELATONIN; MISOPROSTOL; MONOAMINE OXIDASE B INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; ROTENONE; SELEGILINE; TANGERETIN; TENILSETAM; UBIQUINONE; UNINDEXED DRUG;

ACUTE DISEASE; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CELL DEATH; CELL FUNCTION; CELL LOSS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DEGENERATIVE DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; HUMAN; HUNTINGTON CHOREA; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SIDE EFFECT;

ANIMALS; ANTIOXIDANTS; FREE RADICALS; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 0036799799     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.10.1407     Document Type: Review

References (373)

1. MARKESBERY WR, CARNEY JM: Oxidative alterations in Alzheimer's disease. Brain Pathol. (1999) 9:133-146.
2. JOSEPH J, SHUKITT-HALE B, DENISOVA NA, MARTIN A, PERRY G, SMITH MA: Copernicus revisited: amyloid β in Alzheimer's disease. Neurobiol. Aging (2001) 22:131-146.
3. ZHANG Y, DAWSON VL, DAWSON TM: Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. (2000) 7:240-250.
4. FOLEY P, RIEDERER P: Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease. J. Neurol. (2000) 247(Suppl. 2):II82-II94.
5. BROWNE SE, FERRANTE RJ, BEAL MF: Oxidative stress in Huntington's disease. Brain Pathol. (1999) 9:147-163.
6. COOKSON MR, SHAW PJ: Oxidative stress and motor neurone disease. Brain Pathol. (1999) 9:165-186.
7. SAYRE LM, SMITH MA, PERRY G: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. (2001) 8:721-738.
8. GIASSON BI, DUDA JE, MURRAY I et al.: Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science (2000) 290:985-989.
9. PAXINOU E, CHEN Q, WEISSE M et al.: Induction of α-synuclein aggregation by intracellular nitrative insult. J. Neurosci. (2001) 21:8053-8061.
10. GOLDBERG MS, LANSBURY PT. Is there a cause-and-effect relationship between a synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. (2000) 2:E115-E119.
11. PERRY G, AVILA J, ESPEY MG, WINK DA, ATWOOD CS, SMITH MA: Biochemistry of neurodegeneration. Science (2001) 291:595-596.
12. SMITH MA, HARRIS PL, SAYRE LM, BECKMAN JS, PERRY G: Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. (1997) 17:2653-2657.
13. WALSH DM, HARTLEY DM, KUSUMOTO Y et al.: Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. (1999) 274:25945-25952.
14. HEAD E, GARZON-RODRIGUEZ W, JOHNSON JK, LOTT IT, COTMAN CW, GLABE C: Oxidation of Aβ and plaque biogenesis in Alzheimer's disease and Down's syndrome. Neurobiol. Dis. (2001) 8:792-806.
15. SCHWEERS O, MANDELKOW EM, BIERNAT J, MANDELKOW E: Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. USA (1995) 92:8463-8467.
16. LOVELL MA, XIE C, MARKESBERY WR: Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging (2001) 22:187-194.
17. FROST MT, HALLIWELL B, MOORE KP: Analysis of free and protein-bound nitrotyrosine in human plasma by a gas chromatography/mass spectrometry method that avoids nitration artifacts. Biochem. J. (2000) 345:453-458.
18. HALLIWELL B: Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat. Res. (1999) 443:37-52.
19. NUNOMURA A, PERRY G, PAPPOLLA MA et al.: Neuronal oxidative stress precedes amyloid-β deposition in Down's syndrome. J. Neuropathol. Exp. Neurol. (2000) 59:1011-1017.
20. PRATICO D, URYU K, LEIGHT S, TROJANOSWKI JQ, LEE VM: Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. (2001) 21:4183-4187.
21. BETARBET R, SHERER TB, MACKENZIE G, GARCIA-OSUNA M, PANOV AV, GREENAMYRE JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. (2000) 3:1301-1306.
22. KOWALL NW, HANTRAYE P, BROUILLET E, BEAL MF, MCKEE AC, FERRANTE RJ: MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport (2000) 11:211-213.
23. FERRANTE RJ, ANDREASSEN OA, JENKINS BG et al.: Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. (2000) 20: 4389-4397.
24. HARMAN D: Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging (1993) 3:60-80.
25. HARMAN D: Extending the functional life span. Exp. Gerontol. (1998) 33:95-112.
26. BECKMAN KB, AMES BN: The free radical theory of aging matures. Physiol. Rev. (1998) 78:547-581.
27. MARTIN GM, AUSTAD SN, JOHNSON TE: Genetic analysis of ageing: role of oxidative damage and environmental stresses. Nat. Genet. (1996) 13:25-34.
28. HARMAN D: A hypothesis on the pathogenesis of Alzheimer's disease. Ann. NY Acad. Sci. (1996) 786:152-168.
29. SIES H: Strategies of antioxidant defense. Eur. J. Biochem. (1993) 215:213-219.
30. BENDER E, KADENBACH B: The allosteric ATP-inhibition of cytochrome c oxidase activity is reversibly switched on by cAMP-dependent phosphorylation. FEBS Lett. (2000) 466:130-134.
31. KADENBACH B, HUTTEMANN M, ARNOLD S, LEE I, BENDER E: Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase. Free Radic. Biol. Med. (2000) 29:211-221.
32. AMES BN: Micronutrients prevent cancer and delay aging. Toxicol. Lett. (1998) 102 103:5-18.
33. BOVERIS A, CHANCE B: The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem. J. (1973) 134:707-716.
34. BOVERIS A, CADENAS E: Mitochondrial production of hydrogen peroxide: regulation by nitric oxide and the role of ubisemiquinone. IUBMB Life (2000) 50:245-250.
35. SHIINO A, MATSUDA M, HANDA J, CHANCE B: Poor recovery of mitochondrial redox state in CA1 after transient forebrain ischemia in gerbils. Stroke (1998) 29:2421-2424.
36. WALLACE DC: A mitochondrial paradigm for degenerative diseases and ageing. Novartis Found. Symp. (2001) 235:247-263.
37. BEAL MF: Mitochondrial dysfunction in neurodegenerative diseases. Biochim. Biophys. Acta (1998) 1366:211-223.
38. CASSARINO DS, BENNETT JP: An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Brain Res. Rev. (1999) 29:1-25.
39. NICOTERA P, LIPTON SA: Excitotoxins in neuronal apoptosis and necrosis. J. Cereb. Blood Flow Metab. (1999) 19:583-591.
40. FLOYD RA: Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. (1999) 222:236-245.
41. ATAMNA H, PALER-MARTINEZ A, AMES BN: N-t-Butyl hydroxylamine, a hydrolysis product of α-phenyl-N-t-butyl nitrone, is more potent in delaying senescence in human lung fibroblasts. J. Biol. Chem. (2000) 275:6741-6748.
42. ATAMNA H, ROBINSON C, INGERSOLL R, ELLIOTT H, AMES BN: N-t-Butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro. FASEB J. (2001) 15:2196-2204.
43. GLENNER GG, WONG CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. (1984) 120:885-890.
44. MASTERS CL, SIMMS G, WEINMAN NA, MULTHAUP G, MCDONALD BL, BEYREUTHER K: Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc. Natl. Acad. Sci. USA (1985) 82:4245-4249.
45. KOSIK KS, JOACHIM CL, SELKOE DJ: Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1986) 83:4044-4048.
46. STEINER H, HAASS C: Intramembrane proteolysis by presenilins. Nat. Rev. Mol. Cell Biol. (2000) 1:217-224.
47. MAYEUX R, SAUNDERS AM, SHEA S et al.: Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. Engl. J. Med. (1998) 338:506-511.
48. BEHL C: Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol. (1999) 57:301-323.
49. SELKOE DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature (1999) 399(Suppl.):A23-A31.
50. PRASAD KN, HOVLAND AR, COLE WC et al.: Multiple antioxidants in the prevention and treatment of Alzheimer's disease: analysis of biologic rationale. Clin. Neuropharmacol. (2000) 23:2-13.
51. CHRISTEN Y: Oxidative stress and Alzheimer's disease. Am. J. Clin. Nutr. (2000) 71(Suppl.):621S-629S.
52. NUNOMURA A, PERRY G, ALIEV G et al.: Cytosolic peroxidative damage is an early event in Alzheimer's disease. J. Neuropathol. Exp. Neurol. (2001) 60:759-767.
53. GALEAZZI L, RONCHI P, FRANCESCHI C, GIUNTA S: In vitro peroxidase oxidation induces stable dimers of β-amyloid (1-42) through dityrosine bridge formation. Amyloid (1999) 6:7-13.
54. KOPPAKA V, AXELSEN PH: Accelerated accumulation of amyloid β proteins on oxidatively damaged lipid membranes. Biochemistry (2000) 39:10011-10016.
55. PERUTZ MF, WINDLE AH: Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature (2001) 412:143-144.
56. GAMES D, ADAMS D, ALESSANDRI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature (1995) 373:523-527.
57. STURCHLER-PIERRAT C, ABRAMOWSKI D, DUKE M et al.: Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc. Natl. Acad. Sci. USA (1997) 94:13287-13292.
58. HOLCOMB L, GORDON MN, MCGOWAN E et al.: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. (1998) 4:97-100.
59. DEWACHTER I, VAN DORPE J, SPITTAELS K et al.: Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin 1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol. (2000) 35:831-841.
60. LEWIS J, DICKSON DW, LIN WL et al: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 293:1487-1491.
61. FEZOUI Y, HARTLEY DM, HARPER JD et al.: An improved method of preparing the amyloid β-protein for fibrillogenesis and neurotoxicity experiments. Amyloid (2000) 7:166-178.
62. BEHL C, DAVIS J, COLE GM, SCHUBERT D: Vitamin E protects nerve cells from amyloid β protein toxicity. Biochem. Biophys. Res. Commun. (1992) 186:944-952.
63. SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease cooperative study. N. Engl. J. Med. (1997) 336:1216-1222.
64. GRUNDMAN M: Vitamin E and Alzheimer's disease: the basis for additional clinical trials. Am. J. Clin. Nutr. (2000) 71 (Suppl.):630S-636S.
65. FILIP V, KOLIBAS E: Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J. Psychiatry Neurosci. (1999) 24:234-243.
66. FREEDMAN M, REWILAK D, XERRI T et al.: L-Deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology (1998) 50:660-668.
67. ALAFUZOFF I, HELISALMI S, HEINONEN EH et al.: Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease. Eur. J. Clin. Pharmacol. (2000) 55:815-819.
68. THAL LJ, CALVANI M, AMATO A, CARTA A et al.: A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. Neurology (2000) 55:805-810.
69. THAL LJ, CARTA A, CLARKE WR et al.: A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology (1996) 47:705-711.
70. SPAGNOLI A, LUCCA U, MENASCE G et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology (1991) 41:1726-1732.
71. PETTEGREW JW, LEVINE J, MCCLURE RJ: Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry (2000) 5:616-632.
72. VIRMANI MA, CASO V, SPADONI A, ROSSI S, RUSSO F, GAETANI F: The action of aceryl-L-carnitine on the neurotoxicity evoked by amyloid fragments and peroxide on primary rat cortical neurones. Ann. NY Acad. Sci. (2001) 939:162-178.
73. GUTZMANN H, HADLER D: Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. J. Neural Transm. Suppl. (1998) 54:301-310.
74. WEYER G, BABEJ-DOLLE RM, HADLER D, HOFMANN S, HERRMANN WM: A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology (1997) 36:73-82.
75. YAMADA K, TANAKA T, HAN D, SENZAKI K, KAMEYAMA T, NABESHIMA T: Protective effects of idebenone and α-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in fats: implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. (1999) 11:83-90.
76. HIRAI K, HAYAKO H, KATO K, MIYAMOTO M: Idebenone protects hippocampal neurons against amyloid β-peptide-induced neurotoxicity in rat primary cultures. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 358:582-585.
77. ADAIR JC, KNOEFEL JE, MORGAN N: Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. Neurology (2001) 57:1515-1517.
78. PAGANINI-HILL A, HENDERSON VW. Estrogen replacement therapy and risk of Alzheimer's disease. Arch. Intern. Med. (1996) 156:2213-2217.
79. TANG MX, JACOBS D, STERN Y et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429-432.
80. WARING SC, ROCCA WA, PETERSEN RC et al.: Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology (1999) 52:965-970.
81. CARLSON MC, ZANDI PP, PLASSMAN BL et al.: Hormone replacement therapy and reduced cognitive decline in older women: The Cache County Study. Neurology (2001) 57:2210-2216.
82. IN 'T VELD BA, RUITENBERG A, HOFMAN A et al.: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. (2001) 345:1515-1521.
83. BREITNER JC, ZANDI PP: Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N. Engl. Med. (2001) 345:1567-1568.
84. ZANDI PP, BREITNER JC: Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol. Aging (2001) 22:811-817.
85. NOURHASHEMI F, GILLETTE-GUYONNET S, ANDRIEU S et al.: Alzheimer's disease: protective factors. Am. J. Clin. Nutr. (2000) 71(Suppl.):643S-649S.
86. MCGEER PL, ROGERS J: Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology (1992) 42:447-449.
87. AKIYAMA H, BARGER S, BARNUM S et al.: Inflammation and Alzheimer's disease. Neurobiol. Aging (2000) 21:383-421.
88. BEHL C, MOOSMANN B, MANTHEY D, HECK S: The female sex hormone oestrogen as neuroprotectant: activities at various levels. Novartis Found. Symp. (2000) 230:221-238.
89. MCEWEN BS, ALVES SE: Estrogen actions in the central nervous system. Endocr. Rev. (1999) 20:279-307.
90. BABIOR BM: Phagocytes and oxidative stress. Am. J. Med. (2000) 109:33-44.
91. HEWETT SJ, ULIASZ TE, VIDWANS AS, HEWETT JA: Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. (2000) 293:417-425.
92. LI Y, MAHER P, SCHUBERT D: A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron (1997) 19:453-463.
93. MAFFEI FACINO R, CARINI M, ALDINI G, SAIBENE L, MACCIOCCHI A: Antioxidant profile of nimesulide, indomethacin and diclofenac in phosphatidylcholine liposomes (PCL) as membrane model. Int. J. Tissue React. (1993) 15:225-234.
94. LAMBAT Z, CONRAD N, ANOOPKUMAR-DUKIE S, WALKER RB, DAYA S: An investigation into the neuroprotective properties of ibuprofen. Metab. Brain Dis. (2000) 15:249-256.
95. WEGGEN S, ERIKSEN JL, DAS P et al.: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (2001) 414:212-216.
96. MOOSMANN B, BEHL C: The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties. Proc. Natl. Acad Sci. USA (1999) 96:8867-8872.
97. OZDEN S, DILDAR K, KADIR YH, GULIZAR K: The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas (2001) 38:165-170.
98. LEAL M, DIAZ J, SERRANO E, ABELLAN J, CARBONELL LF: Hormone replacement therapy for oxidative stress in postmenopausal women with hot flushes. Obstet. Gynecol. (2000) 95:804-809.
99. BHAVNANI BR, CECUTTI A, GERULATH A, WOOLEVER AC, BERCO M: Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women. Menopause (2001) 8:408-419.
100. SHERWIN BB: Can estrogen keep you smart? Evidence from clinical studies. J. Psychiatry Neurosci. (1999) 24:315-321.
101. HENDERSON VW, PAGANINI-HILL A, MILLER BL et al: Estrogen for Alzheimer's disease in women: randomized, double blind, placebo-controlled trial. Neurology (2000) 54:295-301.
102. WANG PN, LIAO SQ, LIU RS et al.: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology (2000) 54:2061-2066.
103. MULNARD RA, COTMAN CW, KAWAS C et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's disease Cooperative Study. JAMA (2000) 283:1007-1015.
104. ASTHANA S, BAKER LD, CRAFT S et al.: High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology (2001) 57:605-612.
105. SHERWIN BB: Oestrogen and cognitive function throughout the female lifespan. Novartis Found. Symp. (2000) 230:188-201.
106. AISEN PS, DAVIS KL, BERG JD et al.: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease Cooperative Study. Neurology (2000) 54:588-593.
107. SCHARF S, MANDER A, UGONI A, VAJDA F, CHRISTOPHIDIS N: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology (1999) 53:197-201.
108. ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 43:1609-1611.
109. VAN GOOL WA, WEINSTEIN HC, SCHELTENS PK, WALSTRA GJ: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet (2001) 358:455-460.
110. HULL M, LIEB K, FIEBICH BL: Anti-inflammatory drugs: a hope for Alzheimer's disease? Expert Opin. Investig. Drugs (2000) 9:671-683.
111. REITER RJ, ACUNA-CASTROVIEJO D, TAN DX, BURKHARDT S: Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann. NY Acad. Sci. (2001) 939:200-215.
112. PAPPOLLA MA, CHYAN YJ, POEGGELER B et al.: An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J. Neural Transm. (2000) 107:203-231.
113. POEGGELER B, MIRAVALLE L, ZAGORSKI MG et al.: Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid β peptide. Biochemistry (2001) 40:14995-15001.
114. CLAPP-LILLY KL, SMITH MA, PERRY G, HARRIS PL, ZHU X, DUFFY LK: Melatonin acts as antioxidant and pro oxidant in an organotypic slice culture model of Alzheimer's disease. Neuroreport (2001) 12:1277-1280.
115. BRUSCO LI, MARQUEZ M, CARDINALI DP: Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinol. Lett. (2000) 21:39-42.
116. DEFEUDIS FV, DRIEU K: Gingko biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr. Drug Targets (2000) 1:25-58.
117. BASTIANETTO S, RAMASSAMY C, DORE S, CHRISTEN Y, POIRIER J, QUIRION R. The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by β-amyloid. Eur. J. Neurosci. (2000) 12:1882-1890.
118. BASTIANETTO S, ZHENG WH, QUIRION R: The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide induced toxicity: involvement of its flavonoid constituents and protein kinase C. J. Neurochem. (2000) 74:2268-2277.
119. WATANABE CM, WOLFFRAM S, ADER P et al: The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc. Natl. Acad Sci. USA (2001) 98:6577-6580.
120. OKEN BS, STORZBACH DM, KAYE JA: The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. Arch. Neurol. (1998) 55:1409-1415.
121. KANOWSKI S, HERRMANN WM, STEPHAN K, WIERICH W, HORR R. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry (1996) 29:47-56.
122. LE BARS PL, KATZ MM, BERMAN N, ITIL TM, FREEDMAN AM, SCHATZBERG AF: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA (1997) 278:1327-1332.
123. VAN DONGEN MC, VAN ROSSUM E, KESSELS AG, SIELHORST HJ, KNIPSCHILD PG: The efficacy of Ginkgo for elderly people with dementia and age associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc. (2000) 48:1183-1194.
124. LIM GP, CHU T, YANG F, BEECH W, FRAUTSCHY SA, COLE GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. (2001) 21:8370-8377.
125. FRAUTSCHY SA, HU W, KIM P et al.: Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology. Neurobiol. Aging (2001) 22:993-1005.
126. CHERNY RA, ATWOOD CS, XILINAS ME et al.: Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 30:665-676.
127. GOURAS GK, BEAL MF: Metal chelator decreases Alzheimer β-amyloid plaques. Neuron (2001) 30:641-642.
128. SMITH MA, HARRIS PL, SAYRE LM, PERRY G: Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA (1997) 94:9866-9868.
129. HUANG X, CUAJUNGCO MP, ATWOOD CS et al.: Cu(II) potentiation of Alzheimer Aβ neurotoxicity. J. Biol. Chem. (1999) 274:37111-37116.
130. CRAPPERMCLACHLAN DR, DALTON AJ, KRUCK TP et al.: Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet (1991) 337:1304-1308.
131. MUNCH G, TANELI Y, SCHRAVEN E et al.: The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J. Neural Transm. Park. Dis. Dement. Sect. (1994) 8:193-208.
132. SHODA H, MIYATA S, LIU BF et al.: Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology (1997) 138:1886-1892.
133. BEHL C, DAVIES JB, LESLEY R, SCHUBERT D: Hydrogen peroxide mediates amyloid β protein toxicity. Cell (1994) 77:817-827.
134. BRUCE AJ, MALFROY B, BAUDRY M: β-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK 8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. USA (1996) 93:2312-2316.
135. BAKER K, MARCUS CB, HUFFMAN K, KRUK H, MALFROY B, DOCTROW SR: Synthetic combined superoxide dismutase/catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. J. Pharmacol. Exp. Ther. (1998) 284:215-221.
136. MALFROY B, DOCTROW SR, ORR PL, TOCCO G, FEDOSEYEVA EV, BENICHOU G: Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell. Immunol. (1997) 177:62-68.
137. CUZZOCREA S, RILEY DP, CAPUTI AP, SALVEMINI D: Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol. Rev. (2001) 53:135-159.
138. RONG Y, DOCTROW SR, TOCCO G, BAUDRY M: EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology. Proc. Natl. Acad. Sci. USA (1999) 96:9897-9902.
139. LANG AE, LOZANO AM: Parkinson's disease. N. Engl. J. Med. (1998) 339:1044-1153.
140. LANG AE, LOZANO AM: Parkinson's disease. N. Engl. J. Med. (1998) 339:1130-1143.
141. SHARON R, GOLDBERG MS, BARJOSEF I, BETENSKY RA, SHEN J, SELKOE DJ: α-Synuclein occurs in lipid rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc. Natl. Acad. Sci. USA (2001) 98:9110-9115.
142. ABELIOVICH A, SCHMITZ Y, FARINAS I et al: Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 25:239-252.
143. MASLIAH E ROCKENSTEIN E, VEINBERGS I et al.: Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science (2000) 287:1265-1269.
144. VAN DER PUTTEN H, WIEDERHOLD KH, PROBST A et al.: Neuropathology in mice expressing human α-synuclein. J. Neurosci. (2000) 20:6021-6029.
145. TABRIZI SJ, ORTH M, WILKINSON JM et al: Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity. Hum. Mol. Genet. (2000) 9:2683-2689.
146. SOUZA JM, GIASSON BI, CHEN Q, LEE VM, ISCHIROPOULOS H: Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. (2000) 275:18344-18349.
147. CONWAY KA, ROCHET JC, BIEGANSKI RM, LANSBURY PT: Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science (2001) 294:1346-1349.
148. SCOTT WK, NANCE MA, WATTS RL et al.: Complete genomic screen in Parkinson's disease: evidence for multiple genes. JAMA (2001) 286:2239-2244.
149. SVEINBJORNSDOTTIR S, HICKS AA, JONSSON T et al.: Familial aggregation of Parkinson's disease in Iceland. N. Engl. J. Med. (2000) 343:1765-1770.
150. TANNER CM, OTTMAN R, GOLDMAN SM et al: Parkinson's disease in twins: an etiologic study. JAMA (1999) 281:341-346.
151. PAGANINI-HILL A: Risk factors for Parkinson's disease: the leisure world cohort study. Neuroepidemiology (2001) 20:118-124.
152. ASCHERIO A, ZHANG SM, HERNAN MA et al.: Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann. Neurol. (2001) 50:56-63.
153. ROSS GW, PETROVITCH H: Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging (2001) 18:797-806.
154. TUCHSEN F. JENSEN AA: Agricultural work and the risk of Parkinson's disease in Denmark, 1981-1993. Scand. J. Work Environ. Health (2000) 26:359-362.
155. BEHARI M, SRIVASTAVA AK, DAS RR, PANDEY RM: Risk factors of Parkinson's disease in Indian patients. J. Neurol. Sci. (2001) 190:49-55.
156. POLYMEROPOULOS MH, LAVEDAN C, LEROY E et al.: Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science (1997) 276:2045-2047.
157. GASSER T: Genetics of Parkinson's disease. J. Neurol. (2001) 248:833-840.
158. MENDIS T, SUCHOWERSKY O, LANG A. GAUTHIER S: Management of Parkinson's disease. A review of current and new therapies. Can. J. Neurol. Sci. (1999) 26:89-103.
159. FAHN S: Parkinson's disease, the effect of levodopa, and the ELLDOPA trial. Arch. Neurol. (1999) 56:529-535.
160. ZESIEWICZ TA, HAUSER RA: Neurosurgery for Parkinson's disease. Semin. Neurol. (2001) 21:91-101.
161. GERLACH M, RIEDERER P: Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. (1996) 103:987-1041.
162. BLUM B, TORCH S, LAMBENG N et al.: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. (2001) 65:135-172.
163. BEAL MF: Experimental models of Parkinson's disease. Nat. Rev. Neurosci. (2001) 2:325-334.
164. LANGSTON JW, BALLARD P, TETRUD JW, IRWIN I: Chronic Parkinsonism in humans due to a product of meperidineanalog synthesis. Science (1983) 219:979-980.
165. NAKAMURA K, BINDOKAS VP, MARKS JD et al.: The selective toxicity of 1-methyl-4-phenylpyridinium to dopaminergic neurons: the role of mitochondrial complex I and reactive oxygen species revisited. Mol. Pharmacol. (2000) 58:271-278.
166. THOENEN H, TRANZER JP: Chemical sympathectomy by selective destruction of adrenergic nerve endings with 6-hydroxydopamine. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. (1968) 261:271-288.
167. BLOOM FE, ALGERI S, GROPPETTI A, REVUELTA A, COSTA E: Lesions of central norepinephrine terminals with 6-OH-dopamine: biochemistry and fine structure. Science (1969) 166:1284-1286.
168. ANDREW R, WATSON DC, BEST SA, MIDGLEY JM, WENLONG H, PETTY RK: The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. (1993) 18:1175-1177.
169. SIMUNI T, STERN MB: Does levodopa accelerate Parkinson's disease? Drugs Aging (1999) 14:399-408.
170. LINERT W, HERLINGER E, JAMESON RE KIENZL E, JELLINGER K, YOUDIM MB: Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta. (1996) 1316:160-168.
171. JELLINGER KA: The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging (1999) 14:115-140.
172. GLINKA Y, TIPTON KF, YOUDIM MB: Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol. (1998) 351:121-129.
173. DAVIDSON C, GOW AJ, LEE TH, ELLINWOOD EH: Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res. Brain Res. Rev. (2001) 36:1-22.
174. XIA XG, SCHMIDT N, TEISMANN P, FERGER B, SCHULZ JB: Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. J. Neurochem. (2001) 79:63-70.
175. NAKAMURA K, WRIGHT DA, WIATR T et al.: Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin. J. Neurochem. (2000) 74:2305-2314.
176. CHOI HJ, JANG YJ, KIM HJ, HWANG O: Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Mol. Pharmacol. (2000) 58:633-640.
177. KOTSONIS P, FROHLICH LG, SHUTENKO ZV, HOREJSI R, PFLEIDERER W, SCHMIDT HH: Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide. Biochem. J. (2000) 346:767-776.
178. LI H, FORSTERMANN U: Nitric oxide in the pathogenesis of vascular disease. J. Pathol. (2000) 190:244-254.
179. WEVER RM, VAN DAMT, VAN RIJN HJ, DE GROOT F, RABELINK TJ: Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem. Biophys. Res. Commun. (1997) 237:340-344.
180. PARKINSON STUDY GROUP: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. (1993) 328:176-183.
181. KIEBURTZ K, MCDERMOTT M, COMO P et al: The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology (1994) 44:1756-1759.
182. PARKINSON STUDY GROUP: Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neurol. (1996) 40:99-107.
183. TETRUD JW, LANGSTON JW: The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 245:519-522.
184. BIRKMAYER W, KNOLL J, RIEDERER P, YOUDIM MB, HARSV, MARTON J: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J. Neural Transm. (1985) 64:113-127.
185. PARKINSON STUDY GROUP: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann. Neurol. (1996) 39:29-36.
186. PARKINSON STUDY GROUP: Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann. Neurol. (1998) 43:318-325.
187. BEN-SHLOMO Y, CHURCHYARD A, HEAD J et al.: Investigation by Parkinson's disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. BMJ (1998) 316:1191-1196.
188. DONNAN PT, STEINKE DT, STUBBINGS C, DAVEY PG, MACDONALD TM: Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology (2000) 55:1785-1789.
189. SHOULSON I, DATATOP: a decade of neuroprotective inquiry. Parkinson study group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neurol. (1998) 44(Suppl. 1):S160-S166.
190. FAHN S: A pilot trial of high-dose α-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. (1992) 32(Suppl.):S128-132.
191. PERRY TL, YONG VW, HANSEN S et al.: α-Tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl 1,2,3,6-tetrahydropyridine. J. Neurol. Sci. (1987) 81:321-331.
192. MIHATSCH W, RUSS H, GERLACH M, RIEDERER P, PRZUNTEK H: Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. J. Neural Transm. Park. Dis. Dement. Sect. (1991) 3:73-78.
193. ODUNZE IN, KLAIDMAN LK, ADAMS JD: MPTP toxicity in the mouse brain and vitamin E. Neurosci. Lett. (1990) 108:346 349.
194. DEXTER DT, BROOKS DJ, HARDING AE et al.: Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies. Ann. Neurol. (1994) 35:298-303.
195. DEXTER DT NANAYAKKARA I, GOSS SAMPSON MA et al.: Nigral dopaminergic cell loss in vitamin E deficient rats. Neuroreport (1994) 5:1773-1776.
196. DEXTER DT, WARD RJ, WELLS FR et al.: α-Tocopherol levels in brain are not altered in Parkinson's disease. Ann. Neurol. (1992) 32:591-593.
197. VATASSERY GT, FAHN S, KUSKOWSKI MA: α-Tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson study group. Neurology (1998) 50:1900-1902.
198. SCHAPIRA AH, COOPER JM, DEXTER D, CLARK JB, JENNER P, MARSDEN CD: Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. (1990) 54:823-827.
199. SCHAPIRA AH, MANN VM, COOPER JM et al.: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. (1990) 55:2142-2145.
200. SHOFFNER JM, WATTS RL, JUNCOS JL, TORRONI A, WALLACE DC: Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann. Neurol. (1991) 30:332-339.
201. SIMON DK, MAYEUX R, MARDER K, KOWALL NW, BEAL ME JOHNS DR: Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology (2000) 54:703-709.
202. EBADI M, GOVITRAPONG P, SHARMA S et al.: Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept. (2001) 10:224-253.
203. LENAZ G: A critical appraisal of the mitochondrial coenzyme Q pool. FEBS Lett. (2001) 509:151-155.
204. JIMENEZ-JIMENEZ FJ, MOLINA JA, DE BUSTOS F et al.: Serum levels of coenzyme Q10 in patients with Parkinson's disease. J. Neural Transm. (2000) 107:177-181.
205. SHULTS CW, HAAS RH, PASSOV D, BEAL MF: Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. (1997) 42:261-264.
206. GOTZ ME, GERSTNER A, HARTH R et al.: Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J. Neural Transm. (2000) 107:41-48.
207. SCHULZ JB, HENSHAW DR, MATTHEWS RT, BEAL MF: Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. (1995) 132:279-283.
208. + produces progressive neuronal degeneration which is mediated by oxidative stress. Exp. Neurol. (1997) 144:193-198.
209. BEAL MF, MATTHEWS RT, TIELEMAN A, SHULTS CW: Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. (1998) 783:109-114.
210. MATTHEWS RT, YANG L, BROWNE S, BALK M, BEAL MF: Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA (1998) 95:8892-8897.
211. STRIJKS E, KREMER HP, HORSTINK MW: Q10 therapy in patients with idiopathic Parkinson's disease. Mol. Aspects Med. (1997) 18(Suppl.):S237-240.
212. SHULTS CW, BEAL MF, FONTAINE D, NAKANO K, HAAS RH: Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology (1998) 50:793-795.
213. MAYEUX R, MARDER K, COTE LJ et al.: The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am. J. Epidemiol. (1995) 142:820-827.
214. BALDERESCHI M, DI CARLO A, ROCCA WA et al.: Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology (2000) 55:1358-1363.
215. MARDER K, TANG MX, ALFARO B et al.: Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology (1998) 50:1141-1143.
216. SAUNDERS-PULLMAN R, GORDON ELLIOTT J, PARIDES M, FAHN S, SAUNDERS HR, BRESSMAN S: The effect of estrogen replacement on early Parkinson's disease. Neurology (1999) 52:1417-1421.
217. FERNANDEZ HH, LAPANE KL: Estrogen use among nursing home residents with a diagnosis of Parkinson's disease. Mov. Disord. (2000) 15:1119-1124.
218. BLANCHET PJ, FANG J, HYLAND K, ARNOLD LA, MOURADIAN MM, CHASE TN: Short-term effects of high dose 17β-estradiol in postmenopausal PD patients: a crossover study. Neurology (1999) 53:91-95.
219. TSANG KL, HO SL, LO SK: Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology (2000) 54:2292-2298.
220. LERANTH C, ROTH RH, ELSWORTH JD, NAFTOLIN E HORVATH TL, REDMOND DE: Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J. Neurosci. (2000) 20:8604-8609.
221. MILLER DB, ALI SF, O'CALLAGHAN JP, LAWS SC: The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. NY Acad. Sci. (1998) 844:153-165.
222. CALLIER S, MORISSETTE M, GRANDBOIS M, PELAPRAT D, DI PAOLO T: Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse (2001) 41:131-138.
223. TARNOPOLSKY MA, MARTIN J: Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology (1999) 52:854-857.
224. TARNOPOLSKY MA, BEAL MF: Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. (2001) 49:561-574.
225. MATTHEWS RT FERRANTE RJ, KLIVENYI P et al.: Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. (1999) 157:142-149.
226. HANTRAYE P, BROUILLET E, FERRANTE R et al.: Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. (1996) 2:1017-1021.
227. FERRANTE RJ, HANTRAYE P, BROUILLET E, BEAL MF: Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. (1999) 823:177-182.
228. IMAM SZ, CROW JP, NEWPORT GD, ISLAM F, SLIKKER W, ALI SF: Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst. Brain Res. (1999) 837:15-21.
229. SALVEMINI D, WANG ZQ, STERN MK, CURRIE MG, MISKO TP: Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc. Natl. Acad. Sci. USA (1998) 95:2659-2663.
230. IMAM SZ, EL-YAZAL J, NEWPORT GD et al.: Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann. NY Acad. Sci. (2001) 939:366-380.
231. PARNHAM M, SIES H: Ebselen: prospective therapy for cerebral ischaemia. Expert Opin. Investig. Drugs (2000) 9:607-619.
232. MASUMOTO H, SIES H. The reaction of 2-(methylseleno)benzanilide with peroxynitrite. Chem. Res. Toxicol. (1996) 9:1057-1062.
233. MOUSSAOUI S, OBINU MC, DANIEL N, REIBAUD M, BLANCHARD V, IMPERATO A: The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neural. (2000) 166:235-245.
234. MATTHEWS RT, KLIVENYI P, MUELLER G et al.: Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol. (1999) 157:120-126.
235. KARLSSON J, EMGARD M, ROSENBLAD C, BRUNDIN P: Treatment with the spin-trap agent α-phenyl-N-tert-butyl nitrone does not enhance the survival of embryonic or adult dopamine neurons. Brain Res. (1998) 805:155-168.
236. FERGER B, TEISMANN P, EARL CD, KUSCHINSKY K, OERTEL WH: The protective effects of PBN against MPTP toxicity are independent of hydroxyl radical trapping. Pharmacol. Biochem. Behav. (2000) 65:425-431.
237. LEVITES Y, WEINREB O, MAOR G, YOUDIM MB, MANDEL S: Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. (2001) 78:1073-1082.
238. DATLA KP, CHRISTIDOU M, WIDMER WW, ROOPRAI HK, DEXTER DT: Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease. Neuroreport (2001) 12:3871-3875.
239. SHAW KM, STERN GM, SANDLER M: Melatonin and parkinsonism. Lancet (1973) 1:271.
240. ACUNA-CASTROVIEJO D, COTOMONTES A, GAIA MONTI M, ORTIZ GG, REITER RJ: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. (1997) 60: PL23-29.
241. ORTIZ GG, CRESPO-LOPEZ ME, MORAN-MOGUEL C, GARCIA JJ, REITER RJ, ACUNA-CASTROVIEJO D: Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol. Lett. (2001) 22:101-108.
242. DABBENI-SALA F, DI SANTO S, FRANCESCHINI D, SKAPER SD, GIUSTI P: Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. (2001) 15:164-170.
243. MORGAN WW, NELSON JF: Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res. (2001) 921:115-121.
244. WILLIS GL, ARMSTRONG SM: A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease. Physiol. Behav. (1999) 66:785-795.
245. MCGEER PL, YASOJIMA K, MCGEER EG: Inflammation in Parkinson's disease. Adv. Neurol. (2001) 86:83-89.
246. KURKOWSKA-JASTRZEBSKA I, WRONSKA A, KOHUTNICKA M, CZLONKOWSKI A, CZLONKOWSKA A: The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse. Exp. Neurol. (1999) 156:50-61.
247. FERGER B, TEISMANN P, EARL CD, KUSCHINSKY K, OERTEL WH: Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch. Pharmacol. (1999) 360:256-261.
248. TEISMANN P, FERGER B: Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 39:167-174.
249. PASINETTI GM: Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. (1998) 54:1-6.
250. CHASE TN: Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology (1998) 50(5 Suppl. 5):S17-23.
251. GRUNBLATT E, MANDEL S, MAOR G, YOUDIM MB: Effects of R- and S-apomorphine on MPTP-induced nigrostriatal dopamine neuronal loss. J. Neurochem. (2001) 77:146-156.
252. FORNAI F, BATTAGLIA G, GESI M, ORZI F, NICOLETTI F, RUGGIERI S: Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res. (2001) 898:27-35.
253. DOS SANTOS EL-BACHA R, DAVAL J, KOZIEL V, NETTER P, MINN A: Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants. Biochem. Pharmacol. (2001) 61:73-85.
254. MURALIKRISHNAN D, EBADI M: SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. (2001) 892:241-247.
255. IIDA M, MIYAZAKI I, TANAKA K, KABUTO H, IWATA-ICHIKAWA E, OGAWA N: Dopamine D2 receptor mediated antioxiclant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. (1999) 838:51-59.
256. BOZZI Y, VALLONE D, BORRELLI E: Neuroprotective role of dopamine against hippocampal cell death. J. Neurosci. (2000) 20:8643-8649.
257. CEPEDA C, HURST RS, ALTEMUS KL et al.: Facilitated glutamatergic transmission in the striatum of D2 dopamine receptor deficient mice. J. Neurophysiol. (2001) 85:659-670.
258. ANDERSON DW, NEAVIN T, SMITH JA, SCHNEIDER JS: Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res. (2001) 905:44-53.
259. ISHIGE K, CHEN Q, SAGARA Y, SCHUBERT D: The activation of dopamine D4 receptors inhibits oxidative stress-induced nerve cell death. J. Neurosci. (2001) 21:6069-6076.
260. VONSATTEL JP, DIFIGLIA M: Huntington's disease. J. Neuropathol. Exp. Neurol. (1998) 57:369-384.
261. SCHERZINGER E, LURZ R, TURMAINE M et al.: Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell(1997) 90:549-558.
262. DIFIGLIA M, SAPP E, CHASE KO et al.: Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 277:1990 1993.
263. PERUTZ MF: Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. (1999) 24:58-63.
264. YAMAMOTO A, LUCAS JJ, HEN R: Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell (2000) 101:57-66.
265. NUCIFORA EC, SASAKI M, PETERS ME et al.: Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 291:2423-2428.
266. WOLOZIN B, BEHL C: Mechanisms of neurodegenerative disorders: Part 1: Protein Aggregates. Arch. Neurol. (2000) 57:793-796.
267. WOLOZIN B, BEHL C: Mechanisms of neurodegenerative disorders: Part 2: Control of cell death. Arch. Neurol. (2000) 57:801-804.
268. GUSELLA JF, MACDONALD ME: Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. (2001) 1:109-115.
269. ALAM ZI, HALLIWELL B, JENNER P: No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. J. Neurochem. (2000) 75:840-846.
270. KOROSHETZ WJ, JENKINS BG, ROSEN BR, BEAL MF: Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. (1997) 41:160-165.
271. FEIGIN A, KIEBURTZ K, COMO P et al.: Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord. (1996) 11:321-323.
272. RANEN NG, PEYSER CE, COYLE JT et al.: A controlled trial of idebenone in Huntington's disease. Mov. Disord. (1996) 11:549-554.
273. HUNTINGTON STUDY GROUP: A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology (2001) 57:397-404.
274. HUNTINGTON STUDY GROUP: Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. Neurology (1998) 50:1366-1373.
275. BLANCHET PJ, KONITSIOTIS S, HYLAND K, ARNOLD LA, PETTIGREW KD, CHASE TN: Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger. Exp. Neurol. (1998) 153:214-222.
276. ABE K, MORITA S, KIKUCHI T, ITOYAMA Y: Protective effect of a novel free radical scavenger, OPC-14117, on wobbler mouse motor neuron disease. J. Neurosci. Res. (1997) 48:63-70.
277. PEYSER CE, FOLSTEIN M, CHASE GA et al.: Trial of D-α-tocopherol in Huntington's disease. Am. J. Psychiatry (1995) 152:1771-1775.
278. BROUILLET E, CONDE F, BEAL MF, HANTRAYE P: Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. (1999) 59:427-468.
279. BROUILLET E, JENKINS BG, HYMAN BT et al.: Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J. Neurochem. (1993) 60:356-359.
280. LA FONTAINE MA, GEDDES JW, BANKS A, BUTTERFIELD DA: 3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res. (2000) 858:356-362.
281. MATTHEWS RT, YANG L, JENKINS BG et al.: Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. (1998) 18:156-163.
282. SHEAR DA, HAIK KL, DUNBAR GL: Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. Neuroreport (2000) 11:1833-1837.
283. ANDREASSEN OA, FERRANTE RJ, DEDEOGLU A, BEAL ME: Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport (2001) 12:3371-3373.
284. NAKAO N, BRUNDIN P: Effects of α-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience (1997) 76:749-761.
285. BINIENDA Z, JOHNSON JR, TYLER-HASHEMI AA et al.: Protective effect of L-carnitine in the neurotoxicity induced by the mitochondrial inhibitor 3-nitropropionic acid (3-NPA). Ann. NY Acad. Sci. (1999) 890:173-178.
286. GRAMSBERGEN JB, SANDBERG M, KORNBLIT B, ZIMMER J: Pyruvate protects against 3-nitropropionic acid induced neurotoxicity in corticostriatal slice cultures. Neuroreport (2000) 11:2743-2747.
287. KASHIWAYA Y, TAKESHIMA T, MORI N, NAKASHIMA K, CLARKE K, VEECH RL: D-β-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc. Natl. Acad. Sci. USA (2000) 97:5440-5444.
288. VEECH RL, CHANCE B, KASHIWAYA Y, LARDY HA, CAHILL GF: Ketone bodies, potential therapeutic uses. IUBMB Life (2001) 51:241-247.
289. RIVAS-ARANCIBIA S, RODRIGUEZ AI, ZIGOVA T et al.: Taurine increases rat survival and reduces striatal damage caused by 3-nitropropionic acid. Int. J. Neurosci. (2001) 108:55-67.
290. ARUOMA OI, HALLIWELL B, HOEY BM, BUTLER J: The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem. J. (1988) 256:251-255.
291. RODRIGUES CM, STIEERS CL, KEENE CD et al.: Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition. J. Neurochem. (2000) 75:2368-2379.
292. HELLER-STILB B, VAN ROEYEN C, RASCHER K et al.: Disruption of the taurine transporter gene (taut) leads to retinal degeneration in mice. FASEB J. (2001) 15:42-59.
293. ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59-62.
294. AL-CHALABI A, LEIGH PN: Recent advances in amyotrophic lateral sclerosis. Curr. Opin. Neurol. (2000) 13:397-405.
295. VINCETI M, NACCI G, ROCCHI E et al.: Mortality in a population with long-term exposure to inorganic selenium via drinking water. J. Clin. Epidemiol. (2000) 53:1062-1068.
296. NELSON LM, MATKIN C, LONGSTRETH WT, MCGUIRE V: Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am. J. Epidemiol. (2000) 151:164-173.
297. NELSON LM, MCGUIRE V, LONGSTRETH WT, MATKIN C: Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumption. Am. J. Epidemiol. (2000) 151:156-163.
298. GURNEY ME: Transgenic animal models of familial amyotrophic lateral sclerosis. J. Neurol. (1997) 244(Suppl. 2):S15-S20.
299. BRUIJN LI, BEAL MF, BECHER MW et al.: Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. USA (1997) 94:7606-7611.
300. GURNEY ME: What transgenic mice tell us about neurodegenerative disease. Bioessays (2000) 22:297-304.
301. LEE M, HYUN D, JENNER P, HALLIWELL B: Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J. Neurochem. (2001) 76:957-965.
302. JOHNSTON JA, DALTON MJ, GURNEY ME, KOPITO RR: Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA (2000) 97:12571-12576.
303. SHAW PJ, EGGETT CJ: Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J. Neurol. (2000) 247(Suppl. 1):117-127.
304. PARKES TL, ELIA AJ, DICKINSON D, HILLIKER AJ, PHILLIPS JP, BOULIANNE GL: Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurones. Nat. Genetics (1998) 19:171-174.
305. JUNG C, RONG Y, DOCTROW S, BAUDRY M, MALFROY B, XU Z: Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. (2001) 304:157-160.
306. PODUSLO JF, WHELAN SL, CURRAN GL, WENGENACK TM: Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics. Ann. Neurol. (2000) 48:943-947.
307. GURNEY ME, CUTTING FB, ZHAI P et al.: Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. (1996) 39:147-157.
308. DESNUELLE C, DIB M, GARREL C, FAVIER A: A double-blind, lacebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2001) 2:9-18.
309. KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. (1999) 5:347-350.
310. ANDREASSEN OA, JENKINS BG, DEDEOGLU A et al.: Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. (2001) 77:383-390.
311. ANDREASSEN OA, DEDEOGLU A, FRIEDLICH A et al.: Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp. Neurol. (2001) 168:419-424.
312. NAGANO S, OGAWA Y, YANAGIHARA T, SAKODA S: Benefit of a combined treatment with trientine and ascorbate in familial amyotrophic lateral sclerosis model mice. Neurosci. Lett. (1999) 265:159-162.
313. ANDREASSEN OA, DEDEOGLU A, KLIVENYI P, BEAL ME, BUSH AI: N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport (2000) 11:2491-2493.
314. JAARSMA D, GUCHELAAR HJ, HAASDIJK E, DE JONG JM, HOLSTEGE JC: The antioxidant N-acetylcysteine does not delay disease onset and death in a transgenic mouse model of amyotrophic lateral sclerosis. Ann. Neurol. (1998) 44:293.
315. HENDERSON JT, JAVAHERI M, KOPKO S, RODER JC: Reduction of lower motor neuron degeneration in wobbler mice by N-acetyl-L-cysteine. J. Neurosci. (1996) 16:7574-7582.
316. LOUWERSE ES, WEVERLING GJ, BOSSUYT PM, MEYJES FE, DE JONG JM: Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch. Neurol. (1995) 52:559-564.
317. VYTH A, TIMMER JG, BOSSUYT PM, LOUWERSE ES, DE JONG JM: Survival in patients with amyotrophic lateral sclerosis, treated with an a of antioxidants. J. Neurol. Sci. (1996) 139(Suppl.):99-103.
318. CUDKOWICZ ME, SEXTON PM, ELLIS T et al.: The pharmacokinetics and pharmacodynamics of procysteine in amyotrophic lateral sclerosis. Neurology (1999) 52:1492-1494.
319. LANGE DJ, MURPHY PL, DIAMOND B et al.: Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch. Neurol. (1998) 55:93-96.
320. MOOSMANN B, SKUTELLA T, BEYER K, BEHL C: Protective activity of aromatic amines and imines against oxidative nerve cell death. Biol. Chem. (2001) 382:1601-1612.
321. GILGUN-SHERKI Y, MELAMED E, OFFEN D: Oxidative stress-induced neurodegenerative diseases: the need for antioxidants that penetrate the blood-brain barrier. Neuropharmacology (2001) 40:959-975.
322. FISCHER H, GOTTSCHLICH R, SEELIG A: Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membrane Biol. (1998) 165:201-211.
323. MOOSMANN B, BEHL C: Cytoprotective antioxidant function of tyrosine and tryptophan residues in transmembrane proteins. Eur. J. Biochem. (2000) 267:5687-5692.
324. MOOSMANN B, BEHL C: Dietary phenols: antioxidants for the brain? Nutr. Neurosci. (2000) 3:1-10.
325. ALPHA-TOCOPHEROL, BETA-CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. (1994) 330:1029-1035.
326. ROWE PM: β-Carotene takes a collective beating. Lancet (1996) 347:249.
327. AMES BN, GOLD LS: The prevention of cancer. Drug Metab. Rev. (1998) 30:201-223.
328. MASAKI KH, LOSONCZY KG, IZMIRLIAN G et al.: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology (2000) 54:1265-1272.
329. DESCHAMPS V, BARBERGER-GATEAU P, PEUCHANT E, ORGOGOZO JM: Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress. Neuroepidemiology (2001) 20:7-15.
330. CANTUTI-CASTELVETRI I, SHUKITT-HALE B, JOSEPH JA: Neurobehavioural aspects of antioxidants in aging. Int. J. Dev. Neurosci. (2000) 18:367-381.
331. HALLIWELL B: Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic. Res. (1996) 25:57-74.
332. HALLIWELL B: The antioxidant paradox. Lancet (2000) 335:1179-1180.
333. TALALAY P, TALALAY P: The importance of using scientific principles in the development of medicinal agents from plants. Acad. Med. (2001) 76:238-247.
334. LANGSTON JW, FORNO LS, TETRUD J, REEVES AG, KAPLAN JA, KARLUK D: Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. (1999) 46:598-605.
335. VINGERHOETS FJ, SNOW BJ, TETRUD JW, LANGSTON JW, SCHULZER M, CALNE DB: Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol. (1994) 36:765-770.
336. ROSENOW F, HERHOLZ K, LANFERMANN H et al.: Neurological sequelae of cyanide intoxication - the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings. Ann. Neurol. (1995) 38:825-828.
337. HUANG CC, LU CS, CHU NS et al.: Progression after chronic manganese exposure. Neurology (1993) 43:1479-1483.
338. LYE TC, SHORES EA: Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol. Rev. (2000) 10:115-129.
339. CLARKE G, COLLINS RA, LEAVITT BR et al.: A one-hit model of cell death in inherited neuronal degenerations. Nature (2000) 406:195-199.
340. CLARKE G, LUMSDEN CJ, MCINNES RR: Inherited neurodegenerative diseases: the one-hit model of neurodegeneration. Hum. Mol. Genet. (2001) 10:2269-2275.
341. PRESTERA T, TALALAY P: Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. Proc. Natl. Acad. Sci. USA (1995) 92:8965-8969.
342. PRESTERA T, ZHANG Y, SPENCER SR, WILCZAK CA, TALALAY P: The electrophile counterattack response: protection against neoplasia and toxicity. Adv. Enzyme Regul. (1993) 33:281-296.
343. AMES BN, GOLD LS: Misconceptions on pollution and the causes of cancer. Angew. Chem. Int. Ed. (1990) 29:1197-1208.
344. GOLD LS, SLONE TH, AMES BN: What do animal cancer tests tell us about human cancer risk? Overview of analyses of the carcinogenic potency database. Drug Metab. Rev. (1998) 30:359-404.
345. FIANDER H, SCHNEIDER H: Compounds that induce isoforms of glutathione S-transferase with properties of a critical enzyme in defense against oxidative stress. Biochem. Biopbys. Res. Commun. (1999) 262:591-595.
346. ESTERBAUER H, SCHAUR RJ, ZOLLNER H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. (1991) 11:81-128.
347. SAYRE LM, ZELASKO DA, HARRIS PL, PERRY G, SALOMON RG, SMITH MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. (1997) 68:2092-2097.
348. CALINGASAN NY, UCHIDA K, GIBSON GE: Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem. (1999) 72:751-756.
349. LOVELL MA, EHMANN WD, BUTLER SM, MARKESBERY WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's diesease. Neurology (1995) 45:1594-1601.
350. YAN SD, CHEN X, SCHMIDT AM et al.: Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc. Natl. Acad. Sci. USA (1994) 91:7787-7791.
351. TAKEDA A, SMITH MA, AVILA J et al.: In Alzheimer's disease, heme oxygenase is coincident with Alz5O, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem. (2000) 75:1234-1241.
352. LOSKE C, GERDEMANN A, SCHEPL W et al.: Transition metal-mediated glycoxidation accelerates cross-linking of amyloid peptide. Eur. J. Biochem. (2000) 267:4171-4178.
353. KRUMAN I, BRUCE-KELLER AJ, BREDESEN D, WAEG G, MATTSON MP: Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. (1997) 17:5089-5100.
354. XIE C, LOVELL MA, MARKESBERY WR: Glutathione transferase protects neuronal cultures against 4-hydroxynonenal toxicity. Free Radic. Biol. Med. (1998) 25:979-988.
355. GAO X, DINKOVA-KOSTOVA AT, TALALAY P: Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. USA (2001) 98:15221-15226.
356. FIANDER H, SCHNEIDER H: Dietary ortho-phenols that induce glutathione S-transferase and increase the resistance of cells to hydrogen peroxide are potential cancer chemopreventives that act by two mechanisms: the alleviation of oxidative stress and the detoxification of mutagenic xenobiotics. Cancer Lett. (2000) 156:117-124.
357. HUBATSCH I, RIDDERSTROM M, MANNERVIK B: Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. Biochem. J. (1998) 330:175-179.
358. BEHL C: Apoptosis and Alzheimer's disease. J. Neural Transm. (2000) 107:1325-1344.
359. MATTSON M: Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. (2000) 1:120-129.
360. RAINA AK, HOCHMAN A, ZHU X et al.: Abortive apoptosis in Alzheimer's disease. Acta Neuropathol. (2001) 101:305-310.
361. ISHIGE K, SCHUBERT D, SAGARA Y: Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol, Med. (2001) 30:433-446.
362. CHOI JA, KIM JY, LEE JY et al.: Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int. Oncol. (2001) 19:837-844.
363. WENZEL U, KUNTZ S, BRENDEL MD, DANIEL H: Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res. (2000) 60:3823-3831.
364. LINFORD NJ, YANG Y, COOK DG, DORSA DM: Neuronal apoptosis resulting from high doses of the isoflavone genistein: role for calcium and p42/44 mitogen-activated protein kinase. J. Pharmacol. Exp. Ther. (2001) 299:67-75.
365. GALATI G, TENG S, MORIDANI MY, CHAN TS, O'BRIEN PJ: Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics. Drug Metab. Drug Interact. (2000) 17:311-349.
366. KLATT P, MOLINA EP, DE LACOBA MG et al.: Redox regulation of c-Jun DNA binding by reversible S-glutathiolation. FASEB J. (1999) 13:1481-1490.
367. COTGREAVE IA, GERDES RG: Recent trends in glutathione biochemistry-glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation? Biochem. Biophys. Res. Commun. (1998) 242:1-9.
368. SIAN J, DEXTER DT LEES AJ et al.: Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. (1994) 36:348-355.
369. OWEN AD, SCHAPIRA AH, JENNER P, MARSDEN CD: Oxidative stress and Parkinson's disease. Ann. NY Acad. Sci. (1996) 786:217-223.
370. OLNEY JW, ZORUMSKI C, PRICE MT, LABRUYERE J: L-cysteine, a bicarbonate-sensitive endogenous excitotoxin. Science (1990) 248:596-599.
371. YEH MW, KAUL M, ZHENG J et al.: Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of L-cysteine. J. Immunol. (2000) 164:4265-4270.
372. GUTZMANN H, KUHL KP, HADLER D, RAPP MA: Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. Pharmacopsychiatry (2002) 35:12-18.
373. SHOULSON I, OAKES D, FAHN S et al.: Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann. Neurol. (2002) 51:604-612.